Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 117 Florida 107 Georgia 51 New York 51 Arizona 50

Trials with a site in California

117 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Pfizer
Phase 3
900
California, Florida, New Jersey, Pennsylvania, Texas, Washington
2026-11-17
Not yet open
Pfizer
Phase 3
750
Arizona, California, Florida, Georgia, Idaho, Oregon, Tennessee, Texas
2026-10-29
Recruiting
Pfizer
Phase 3
656
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2026-10-26
Recruiting
Pfizer
Phase 1
144
California
2026-10-16
Recruiting
Pfizer
Phase 3
660
Alabama, California, Florida, Indiana, Kentucky, Michigan, Mississippi, Missouri
2026-09-30
Recruiting
Pfizer
Phase 3
258
Alabama, Arkansas, California, Florida, Michigan, Minnesota, Texas
2026-09-17
Recruiting
Pfizer
Phase 3
600
Arizona, California, Connecticut, District of Columbia, Idaho, Indiana, New Jersey, Ohio
2026-09-09
Active, closed
Pfizer
Phase 3
4,701
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa
2026-09-08
Recruiting
Pfizer
Phase 3
440
California, Colorado, District of Columbia, Georgia, Iowa, Louisiana, Maryland, Missouri
2026-08-31
Recruiting
Pfizer
Phase 3
400
Arizona, California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan
2026-08-26
Recruiting
Pfizer
Phase 3
1,375
Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana
2026-08-24
Recruiting
Pfizer
Phase 3
1,100
California, Florida, Maryland, Michigan, New Jersey, North Carolina, Oklahoma, Tennessee
2026-08-20
Recruiting
Pfizer
Phase 3
375
Alabama, Arizona, California, Florida, Georgia, North Dakota, Texas
2026-08-17
Recruiting
Pfizer
Phase 3
336
California, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts, Michigan
2026-07-30
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
Pfizer
Phase 2
40
California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio
2026-07-02
Recruiting
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Massachusetts, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
Pfizer
Phase 3
1,200
Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts
2026-06-15
Recruiting
Pfizer
Phase 3
954
California, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Nebraska
2026-06-10
Recruiting
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
Pfizer
Phase 4
400
California, Florida, Illinois, Indiana, Kansas, Massachusetts, Michigan, Minnesota
2026-05-28
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Kansas, Maryland, Missouri, Nevada
2026-05-14
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
Pfizer
Observational
150
California
2026-04-24
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Active, closed
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
Pfizer
Phase 2/3
1,156
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2026-02-11
Recruiting
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, Massachusetts, New Jersey, New York, Oregon
2026-01-30
Recruiting
Pfizer
Phase 1
28
California, Florida, Minnesota
2026-01-28
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2026-01-06
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
Pfizer
Phase 1
26
California, Florida
2025-12-22
Active, closed
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-11
Recruiting
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Recruiting
Pfizer
Phase 3
450
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Recruiting
Pfizer
Phase 1/2
138
Arizona, California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-12-01
Recruiting
Pfizer
Phase 2
165
Arizona, California, Florida, New York, Ohio, Pennsylvania
2025-11-20
Active, closed
Pfizer
Phase 2
128
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky
2025-11-13
Recruiting
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, New York
2025-10-30
Recruiting
Pfizer
Phase 2/3
982
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Hawaii
2025-10-03
Recruiting
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Recruiting
Pfizer
Phase 3
140
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-09-10
Recruiting
Pfizer
Phase 3
6,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland
2025-08-25
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Active, closed
Pfizer
Phase 1
200
California, Florida, New York, Ohio, Tennessee
2025-08-11
Active, closed
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Active, closed
Pfizer
Phase 3
151
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-07-24
Recruiting
Pfizer
Phase 3
714
Alaska, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine
2025-07-23
Active, closed
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Recruiting
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Active, closed
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Oregon
2025-06-30
Recruiting
Pfizer
Phase 2
620
California, Florida, Illinois, Indiana, Maryland, Nebraska, Ohio, Texas
2025-06-19
Recruiting
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
Pfizer
Phase 1
15
California, North Carolina
2025-05-13
Recruiting
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Recruiting
Pfizer
Phase 3
550
Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas
2025-04-16
Recruiting
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Recruiting
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Active, closed
Pfizer
Phase 3
1,037
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Recruiting
Pfizer
Phase 3
2,330
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-08
Active, closed
Pfizer
Phase 3
636
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
Pfizer
Phase 1
119
California, Florida, Michigan, Pennsylvania
2024-11-05
Active, closed
Pfizer
Phase 3
900
Arizona, Arkansas, California, Illinois, New York, Washington
2024-10-22
Active, closed
Pfizer
Phase 3
609
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maine
2024-10-21
Recruiting
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Active, closed
Pfizer
Observational
300
Arizona, California, Colorado, Florida, Illinois, Maryland, New Jersey, New York
2024-09-17
Active, closed
Pfizer
Observational
450
Alabama, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Minnesota
2024-08-07
Active, closed
Pfizer
Phase 2
605
Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Kansas, Kentucky
2024-07-25
Active, closed
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
Pfizer
Phase 3
394
California, Florida, Indiana, Louisiana, Maryland, Michigan, New Mexico, New York
2024-01-19
Active, closed
Pfizer
Phase 3
1,571
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Maryland
2023-11-08
Recruiting
Pfizer
Phase 4
80
California, Colorado, Florida, Michigan, Texas
2023-10-03
Active, closed
Pfizer
Phase 2
507
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2023-08-22
Recruiting
Pfizer
Phase 3
318
Arizona, California, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma
2023-05-20
Recruiting
Pfizer
Phase 2
48
California, New York
2023-04-18
Active, closed
Pfizer
Phase 1/2
936
Arizona, California, Florida, Illinois, Kansas, Minnesota, Missouri, New York
2023-03-23
Active, closed
Pfizer
Phase 3
624
California, Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Mississippi
2023-03-03
Active, closed
Pfizer
Phase 1/2
37
California, Florida, Illinois, Missouri, Texas, Washington
2023-02-23
Recruiting
Pfizer
Phase 3
173
California, Florida, Indiana, Mississippi, New York, Pennsylvania, Washington
2022-12-28
Recruiting
Pfizer
Phase 2
36
Arkansas, California, Florida, Illinois, Massachusetts, Michigan, Ohio, Texas
2022-12-16
Active, closed
Pfizer
Phase 1
59
Arkansas, California, Florida, Georgia, Iowa, Maryland, Massachusetts, New Jersey
2022-12-14
Active, closed
Pfizer
Phase 1
148
Alabama, Arkansas, California, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2022-11-30
Active, closed
Pfizer
Phase 4
319
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Louisiana, Massachusetts
2022-11-21
Recruiting
Pfizer
Observational
12,500
California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-27
Active, closed
Pfizer
Phase 2
35
California
2022-07-07
Active, closed
Pfizer
Phase 3
854
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Michigan
2022-03-25
Active, closed
Pfizer
Phase 1/2
235
California, Massachusetts, Michigan, Missouri, Texas, Washington
2022-03-14
Recruiting
Pfizer
Phase 3
160
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Maryland
2022-03-07
Recruiting
Pfizer
Phase 3
640
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2022-02-28
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
California
2021-12-28
Recruiting
Pfizer
Phase 3
893
California, Colorado, Florida, Louisiana, New Jersey, New York
2021-10-04
Active, closed
Pfizer
Phase 3
77
Arkansas, California, Florida, New Jersey, New York, Pennsylvania, Texas, Washington
2021-09-29
Active, closed
Pfizer
Phase 3
38,861
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-31
Active, closed
Pfizer
Phase 3
118
California, Connecticut, Florida, Georgia, Massachusetts, New York, Ohio, Pennsylvania
2021-08-12
Active, closed
Pfizer
Phase 3
599
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-05-12
Recruiting
Pfizer
Phase 3
600
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-04-28
Recruiting
Pfizer
Phase 3
2,100
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2021-01-15
Active, closed
Pfizer
Phase 3
841
Arizona, California, Florida, Illinois, Louisiana, Minnesota, Missouri, Nebraska
2020-12-21
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer
Phase 2
320
Arizona, California, Connecticut, Florida, Kentucky, Tennessee, Texas, Washington
2020-11-16
Active, closed
Pfizer
Phase 3
114
Arkansas, California, Florida, Iowa, Kansas, North Carolina, Pennsylvania, Utah
2020-11-05
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
Pfizer
Phase 2
430
California, Connecticut, Massachusetts, Michigan, Tennessee, Texas
2020-09-23
Active, closed
Pfizer
Phase 3
1,068
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Maryland
2019-12-30
Active, closed
Pfizer
Phase 3
896
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2019-09-05
Active, closed
Pfizer
Phase 3
51
California, Colorado, Indiana, Mississippi, Pennsylvania
2019-07-29
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Arizona, California, Connecticut, Kansas, Kentucky, Maryland, Massachusetts, Nebraska
2018-04-17
Active, closed
Pfizer
Phase 3
1,054
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2017-12-18
Active, closed
Pfizer
Phase 3
1,068
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2014-12-17
Rows per page Showing 1–117 of 117
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 117 of those studies with a site in California that also match the filters currently applied.

How many clinical trials are recruiting in California?

71 of the 117 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 45 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (California), 117 studies
PhaseStudiesRecruitingShare
Phase 3643854.7%
Phase 2181215.4%
Phase 114912%
Phase 1/2947.7%
Phase 4534.3%
Observational423.4%
Phase 2/3332.6%

Most active sponsors

Lead sponsors with the most studies (California)
Lead sponsorStudiesRecruiting
Pfizer11771
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.